Chinara Maratovna Razzakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chinara Maratovna Razzakova has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
A. Aziz N
Department of Pharmacy Practice, Malaysian Science University (MSU), Shah Alam Campus, Shah Alam, Malaysia
1 shared publicationA. H. Basari
Health Services Division, MAF HQ, Ministry of Defense, Kuala Lumpur, Malaysia
1 shared publicationA. L. Nadiah Loke
School of Pharmacy, KPJ Healthcare University College, Nilai, Malaysia
1 shared publicationA. Md Shariff
Department of Pharmacy, Hospital Tengku Ampuan Rahimah, Klang, Malaysia
1 shared publicationA. W. Izyan
Cyberjaya University College of Medical Sciences, Cyberjaya, Malaysia
1 shared publicationAdeel Aslam
1 shared publication
Latest Publications
- Open Access
- 29 January 2020
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 13 (S1) , 1-19
Abstracts from the 1st JoPPP Conference on Pharmaceutical Policy and Practice
Pharmaceutical industry is one of the main contributors of public health. In a pharmaceutical industry, Data integrity is one of the most important aspect that relates to drug quality, safety, efficacy and purity. Recently, many industries have been given warning letters due to the violation of data integrity and strict action had been taken by international and local regulatory authorities. Data integrity should be a part of pharmaceutical policy. It claims that product has been manufactured after meeting the predetermined specification and quality attributes and showed compliance of testing methods according to the guidelines given in official books. The FDA, USA considers integrity of data, from initial step where it is generated, and extending throughout its life cycle, to be a critical component which ensures that only high quality and safe drugs are manufactured. Hence, it is essential to record each and every detail of drug manufacturing and testing which should comply with cGMP practices. In future, the completeness, consistency, and accuracy of the data will decide the fate of the pharmaceutical companies.
- 29 January 2020
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 13 (S1) , 1-19
Open AccessAbstracts from the 1st JoPPP Conference on Pharmaceutical Policy and Practice
Pharmaceutical industry is one of the main contributors of public health. In a pharmaceutical industry, Data integrity is one of the most important aspect that relates to drug quality, safety, efficacy and purity. Recently, many industries have been given warning letters due to the violation of data integrity and strict action had been taken by international and local regulatory authorities. Data integrity should be a part of pharmaceutical policy. It claims that product has been manufactured after meeting the predetermined specification and quality attributes and showed compliance of testing methods according to the guidelines given in official books. The FDA, USA considers integrity of data, from initial step where it is generated, and extending throughout its life cycle, to be a critical component which ensures that only high quality and safe drugs are manufactured. Hence, it is essential to record each and every detail of drug manufacturing and testing which should comply with cGMP practices. In future, the completeness, consistency, and accuracy of the data will decide the fate of the pharmaceutical companies.